GCL
SABS icon

Glazer Capital LLC’s SAB Biotherapeutics SABS Stock Holding History

Glazer Capital LLC’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-133
Closed -$13K – 852
2021
Q3 		$13K Sell
133
-53,117
-100% -$5.3M ﹤0.01% 884
2021
Q2 		$5.3M Buy
+53,250
New +$5.28M 0.08% 276

Other funds holding SABS

FPB
First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
IFAM
Institutional & Family Asset Management Fort Collins, Colorado $654M AUM 12.29% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 21.71% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
V
Veritable Wilmington, Delaware $6.46B AUM 17.32% 1-Year Est. Return

Glazer Capital LLC's SABS Position: Q4 2021 in Review

Glazer Capital LLC sold out of SAB Biotherapeutics (SABS) in Q4 2021, closing a stake of 133 shares — an estimated $13K sold.

Glazer Capital LLC first reported a position in SABS in Q2 2021 and held it in 2 quarters. The position peaked at $5.3M in Q2 2021. 34 funds tracked by Wall St. Rank hold SABS as of Q4 2021.

  • Glazer Capital LLC reported no remaining SAB Biotherapeutics position as of Q4 2021 after selling out during the quarter.
  • Glazer Capital LLC sold 133 SAB Biotherapeutics shares in Q4 2021, an estimated $13K.
  • Glazer Capital LLC first reported a position in SAB Biotherapeutics in Q2 2021 and held it in 2 quarters.
  • Glazer Capital LLC's SAB Biotherapeutics position peaked at $5.3M in Q2 2021.
  • 34 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q4 2021.

Based on Glazer Capital LLC's 13F filing for Q4 2021, filed 14 Feb 2022.